The drug would be used to treat multiple sclerosis.
Weston-based Biogen Idec is seeking approval from the federal government for its new Multiple Sclerosis drug, according to the Boston Herald. The drug, designed to treat relapsing forms of the condition, comes after one year of study of the medication. The data showed the drug greatly reduced relapses and disability progression. The drug, which is injectible, is called Plegridy. The company said it anticipates hearing of the possible acceptance of the drug within the next few months.
The list was compiled based on several performance factors.
A Weston company has been named to the Boston Globe’s top 100 publicly held companies. The rankings were compiled based on several performance factors including 2012 revenue and one-year profit margins. By ranking, the list includes: Several nearby Waltham firms also made the list. For more information, visit the Boston Globe.
Biogen Idec, based in Weston, reported a strong fourth quarter.
Weston-based Biogen Idec saw its shares climb 7 percent yesterday after reporting strong fourth quarter revenue growth, the Boston Herald reported. According to the Herald, Biogen Idec's fourth quarter revenue grew by 7 percent over the same period last year, bringing the quarter's total revenue to more than $1.4 billion. The firm's earnings per share in the fourth quarter of 2012 came in at $1.23, an increase over the same period in 2011, the Boston Herald reports. The positive fourth quarter numbers were, in fact, negatively impacted by an accumulating tax error related to an overseas facility. The error has been corrected, but fourth quarter shares were negatively impacted by about $.12 per share, according to reports. Biogen Idec is …
